About the Event
Webinar series took place Tuesday, October 25th
Applying model-informed drug discovery and development (MID3) early in development can reduce late-stage risk by determining feasibility of drugging a given target, prioritizing between targets, or defining optimal drug properties for a target product profile. However, the lack of pharmacokinetic (PK) and pharmacodynamic (PD) data available at early stages can make modeling a challenge. For this reason, we developed Early Feasibility Assessment (EFA): a method for making effective dose predictions using mechanistic PK/PD models built from general biophysical principles and parameterized by data that is readily available early in drug discovery.
Applied BioMath Assess™ is a point-and-click, MID3 software for performing EFA across various modalities. This webinar series will discuss scientific case studies demonstrating how you can quickly inform target selection, project clinical dose requirements, design a lead optimization funnel, and identify areas of program risk.
Featured Webinars and Times
12:00PM EST- Checkpoint Inhibitors and TCEs
Title: Early Feasibility Analysis of Biotherapeutics:
- Checkpoint inhibitors: Is target engagement the whole story
- Predicting on-target, off-tumor toxicity of Solitomab, an EpCAM/CD3 BiTE
2:00PM EST- Gene Therapy
Title: LNP-delivered mRNA for UGT1A1 replacement in Crigler-Najjar syndrome type 1 patients
4:00PM EST- Protein Degraders
Title: Guiding Target Selection and Lead Optimization for a PROTAC Targeted Protein Degrader